Fig. 3

Y-27632, Y-33075, and H-1152 prevent microglial cell proliferation and activation in wholemount retinal explants in culture. a Representative confocal images of wholemount retinal explants in culture at DEV 0 and for the control solvent DEV 4 and treated DEV 4 groups (50 µM Y-33075, 100 µM H-1152, and 500 µM Y-27632) immunolabeled with Iba1 (green) at 20 × magnification (n = 6 per group), scale bar = 150 µm. b Representative confocal images of retinal explant cryosections in culture at DEV 0 and for the control solvent DEV 4 and treated DEV 4 groups (50 µM Y-33075, 100 µM H-1152 100 µM and Y-27632 500 µM) immunolabeled with Iba1 (green) and CD68 (red) at 40 × magnification (n = 6 per group), scale bar = 100 µm. (C) Graph displaying the calculated percentages of microglial cells on viable cells (CD11b⁺, CD68⁺ and double CD11b⁺/ CD68⁺) labeled in explants at DEV 4 as determined by flow cytometry analysis. Unpaired t test or Mann–Whitney test were performed between the control and Y-33075-treated group at DEV 4 (n = 7–17/group, *p < 0.05, ****p < 0.0001). Error bars indicate the standard error of the mean